Revolution Medicines Inc

Research Revolution Medicines Inc (RVMD) on Bullrun: market cap USD 45.29B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 45.29B.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 0-USD 1.13B-USD 913.73Mn/a-5.95USD 383.75MUSD 158.70MUSD 1.63B
FY2024USD 0-USD 600.00M-USD 567.74Mn/a-3.58USD 543.06MUSD 135.84MUSD 2.27B
FY2023USD 11.58M-USD 436.00M-USD 358.30Mn/a-3.86USD 696.15MUSD 87.94MUSD 1.83B
FY2022USD 35.38M-USD 249.00M-USD 235.22Mn/a-3.08USD 161.41MUSD 64.95MUSD 685.19M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 45.29Bn/an/an/a
20252025-12-31USD 15.69Bn/an/an/a
20242024-12-31USD 8.13Bn/an/an/a
20232023-12-29USD 4.70Bn/an/an/a
20222022-12-30USD 2.11Bn/an/an/a
20212021-12-31USD 1.87Bn/an/an/a

About Revolution Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Revolution Medicines Inc's market cap?

Revolution Medicines Inc's market capitalization is USD 45.29B.

What does Revolution Medicines Inc do?

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.